Qiagen (QGEN, $48.55) had an outstanding start to the year, driven by solid growth of non-coronavirus test products. No doubt, soaring global demand for test
Are you always behind the latest news? With The Never Too Late Investor’s newsletter, you’ll be up to date on all the latest investment news. Sign up and get the inside scoop on which stocks to watch out for.